New drug tested for rare immune system malfunctions
NCT ID NCT06549114
Summary
This study is testing a drug called leniolisib to see if it is safe and tolerable for people with specific, rare genetic disorders that cause the immune system to malfunction. The study will involve about 12 participants, aged 12 to 75, who have one of these disorders and related health issues like low blood counts or enlarged organs. Each participant will take the drug at increasing doses over several months while doctors monitor for side effects and look for early signs that it might help their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISORDERS (PIDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute of Health
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.